The IMF trims its economic growth forecast again as the U.S.-China trade war continues, Brexit worries linger and inflation remains muted.Economyread more
Citigroup thinks Tesla investors hoping for a post-earnings rally later this week should scrutinize a pair of related financial metrics.Investingread more
Olive branches were extended from both China and the U.S. as the two nations are set to restart face-to-face trade negotiations after a monthlong truce.Marketsread more
Coca-Cola topped Wall Street's expectations for earnings and revenue.Food & Beverageread more
New disclosures show Facebook and Amazon each spent more than $4 million on lobbying activity in the second quarter of 2019.Technologyread more
Boris Johnson, one of the biggest voices in the Brexit movement, wins the Conservative Party leadership race by a 2-1 margin.Europe Politicsread more
Disney can nearly double its earnings by 2024, Morgan Stanley said in a note to clients on Tuesday.Investingread more
Amazon is expected to report its second-quarter earnings on Thursday.Investingread more
The largest residential brokerage company in the U.S. is partnering with the largest online retailer in a strategy to boost sales for both.Real Estateread more
Here are the biggest calls on Wall Street on TuesdayInvestingread more
Canaccord Genuity's Tony Dwyer believes stocks are about to fall as much as 5% from their all-time highs.Trading Nationread more
In the wake of Pfizer's failed merger attempt to facilitate a move overseas for apparent tax purposes, Merck chief Kenneth Frazier told CNBC Wednesday the drugmaker is "very proud" to be an American company.
But the Merck chairman and CEO also said the government needs to modify its high corporate tax code relative to other countries to level the playing field so "U.S.-based companies are no longer at a competitive disadvantage with European and Japanese companies."
Last week, Pfizer abandoned plans to try to buy AstraZeneca, after its British rival rejected the American pharma giant's $116 billion "final offer." The deal would have allowed New York-based Pfizer to move its headquarters to the U.K., where corporate taxes are not as high.
In a "Squawk Box " interview, Frazier didn't want to comment directly on Pfizer's moves, but said: "Over the long term, the intrinsic value creation in the pharmaceutical business comes down to R&D. It comes down to innovation."
He said that's what Merck is focused on for patients and shareholders. "By innovating, we can have sustainable long-term cash flow, which is what creates value."
Earlier this month, Bayer AG of Germany agreed to buy Merck's consumer care business for $14.2 billion.
—By CNBC's Matthew J. Belvedere